End Colon Cancer Coast to Coast
Take action today—start a fundraiser and be part of a nationwide effort to save lives.
What is tumor mutation burden (TMB)?
Tumor mutation burden (TMB) is a measure of the number of mutations carried by tumor cells. Tumors with many mutations have a high mutation burden (high TMB).
Many tumors with a high TMB (equal to or greater than 10) also have the biomarker MSI-H.
In MSI-H tumors, the somatic mutation occurs in one of the DNA mismatch repair genes that also results in MSI-H. These mutations can be passed along to new tumor cells during cell division. A small percentage of tumors with TMB also have the biomarker MSS.
What happens if I have a high TMB?
Knowing the TMB score of a tumor may help predict how well it will respond to immunotherapies.
This can help you and your doctor find the right treatment plan for you.
Related Topics
Other biomarkers
UGT1A1 BiomarkerTop resources
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Last updated
Christy Williams: Biomarker testing leads to successful treatment
Statistics suggested that Christy’s odds of survival were grim, so she leaned into her faith and kept a positive outlook. She tried to control what she could. And, critically, she received biomarker testing.
Last updated
Michelle Cappel: Biomarker testing extends life
Michelle Cappel owes a lot to colorectal cancer biomarker testing — seven years of life and counting.
Last updated